Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease.
Key facts
- Where
- Helsinki, Oulu, Tampere és Turku, FinnországSee the 4 sites
- Phase
- 4. fázis
Where in Finnország
- HUS-YhtymaeHelsinki, FinnországTaking people
- Oulu University HospitalOulu, FinnországTaking people
- Tampere University HospitalTampere, FinnországTaking people
- Turku University HospitalTurku, FinnországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- HUS-Yhtymae
- Trial code
- EU 2024-512475-12-01
- Record updated
- 2024. november 27.
- Original description
Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.Read full original descriptionShow less
Thrombosis prophylaxis and coagulation activation during neoadjuvant treatment in pancreatic cancer - Association to prognosis and recurrence.
Neoadjuvant-treated pancreatic cancer patients are at increased risk of thrombosis. Our aim is to investigate the impact of thromboprophylaxis administered during neoadjuvant treatments on the risk of vascular events and survival prognosis in pancreatic cancer patients in a randomized prospective study.
Inclusion: An adult pancreatic cancer patient for whom neoadjuvant treatments are being planned due to pancreatic cancer.
Exclusion: The study excludes patients, if they have contraindications for using tinzaparin, are already on anticoagulant medication, have had any other active cancer in the past five years or have severe kidney failure or bleeding tendencies.